Project Grant R01HL179339
Award Date 9/12/25
Completion Date 6/30/29
Dollars Obligated $461K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
- This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will develop new pulmonary magnetic resonance imaging (MRI) methods on a novel 0.55 Tesla scanner. The $659,644 project, running from September 2025 to June 2029, will focus on improving the spatial resolution and image contrast of structural lung proton MRI, as well as developing methodology for hyperpolarized xenon imaging at this...
- This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
- This Project Grant award of $108,003.00, provided by the National Heart Lung and Blood Institute under CFDA Program 93.837 Cardiovascular Diseases Research, supports a study on "Early Changes of T2* Measures in Lung Tissues Using Deltate-UTE MRI on Healthy and COPD Patients" at the University of California, San Diego (UCSD). The goal is to develop an advanced ultrashort echo-time (UTE) magnetic resonance imaging (MRI) technique, called TE-UTE, to accurately map T2* values in lung...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $306,530.00 to Spinhance LLC to build, qualify, and evaluate the clinical feasibility of a novel cardiopulmonary imaging device. The device is designed for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129 (HPX), which was recently approved by the FDA. The project aims to develop an MRI-compatible, piston-based...
- The federal Project Grant award, titled "MicroRNAs in Airway Smooth Muscle Function and Asthma," was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $616,814 award, with a start date of January 15, 2025 and a completion date of November 30, 2028, supports research at the President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) to investigate the role of microRNAs in regulating...
- This federal Project Grant award of $429,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop an efficient, contrast-free, 3D whole-lung low-field magnetic resonance imaging (MRI) protocol for the detection of pulmonary embolism (PE). The project, awarded to the Regents of the University of Michigan, will leverage advancements in low-field MRI hardware and deep learning techniques to create a rapid, comfortable, and radiation-free...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- The Project Grant award of $191,913 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to evaluate the use of hyperpolarized xenon-129 MRI as a predictive biomarker for mitigating radiation-induced lung injury (RILI) in lung cancer patients undergoing radiotherapy. The University of Texas MD Anderson Cancer Center will conduct this research, which aims to establish xenon-129 MRI-guided functional avoidance radiotherapy as an...
- The Washington University was awarded a $761,782 Project Grant from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on September 1, 2025, with a completion date of July 31, 2029. The grant supports comprehensive research to investigate the cellular processes resulting in acquired airway ciliopathies, which are characterized by loss of cilia maintenance and impaired airway clearance observed in lung diseases such as asthma and COPD. Key objectives...